Home › Compare › SNIPF vs ABBV
SNIPF yields 5405.41% · ABBV yields 3.06%● Live data
📍 SNIPF pulled ahead of the other in Year 1
Combined, SNIPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SNIPF + ABBV for your $10,000?
Snipp Interactive Inc., a loyalty and promotions company, focuses on developing marketing engagement platforms in the United States, Canada, Ireland, and internationally. Its solutions include shopper marketing promotions, loyalty, rewards, rebates, and receipt processing. The company also engages in designing, executing, and promoting marketing programs. Snipp Interactive Inc. offers SnippCheck, a mobile receipt processing solution that allows brands to execute purchase-based promotions and loyalty programs; SnippWin, a promotion and sweepstakes platform provides various promotions from contests and simple sweepstakes to instant win programs and tiered, multi-level games; and SnippLoyalty, a solution that allows clients to deploy from simple punch-card programs to points-based loyalty programs with rewards stores. It also provides SnippRewards, a rewards platform that offers various rewards, including movie tickets, PayPal, and other money back mechanisms; and SnippInsights Data Analytics, a tool that collects and unifies data across all the programs that clients run on the snipp platform. In addition, the company offers SnippRebates, a SaaS platform that allows brands to set up and manage single-instance or cross-portfolio rebates; and SnippRx, a solution that allows medical practitioners to distribute incentives like coupons and pay-no-more cards direct to patients via text or email. It serves advertising agencies, brands and related marketing, and promotions agencies. Snipp Interactive Inc. was founded in 2007 and is headquartered in Vancouver, Canada.
Full SNIPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.